Arjun Krishnamoorthy

Arjun Krishnamoorthy, Senior Associate, JSA

Arjun’s practice largely focuses on corporate commercial transactions in various sectors, including the life sciences sector, and includes commercial contract advising, M&A, and real estate matters. He also advises clients on various aspects of technology law including data protection. In the life sciences sector, he advises on various aspects of health laws, including contract manufacturing, medical devices, and sale of pharmaceutical products and data protection. Arjun has also advised on regulatory matters under the Drugs and Cosmetics Act, 1940, including on manufacturing and import licenses, and the Narcotic Drugs and Psychotropic Substances Act, 1985, including on manufacturing and import licences. In addition, he assists in the negotiation and documentation of commercial contracts, including service agreements, franchising agreements, and employment and consultancy contracts.

Arjun has been a practicing attorney since 2005, and prior to JSA, worked at Kochhar & Co., at the firm’s Bangalore office

 

Memberships

Karnataka State Bar Council

 

Publications

  • Net Neutrality: A Need for More Transparency, The Financial Express, 10 October 2018
  • Mala Aai Vhhaychay! A look at India’s surrogacy laws, The Hindu, 25 August 2019
  • ‘Not so elementary, my dear Watson!’ Artificial Intelligence and healthcare: are we prepared?, IBA – Healthcare and Lifesciences News, September 2019
  • India’s new telemedicine guidelines – IBA – Healthcare and Lifesciences News, 2020

 

Education

  • BSL LLB, ILS Law College, University of Pune, 2005
  • LLM, Legal Aspects of Medical Practice, Cardiff University, 2006

 

Languages

  • English
  • Hindi
  • Kannada
  • French
  • Tamil

Some of the key assignments in these areas handled and being handled by Arjun amongst others, cover the following:-

  • Advised and assisted a leading biopharmaceutical company in reproductive medicine and women’s health, in (a)undertaking contract manufacturing in India under a loan license; (b) the Drugs and Cosmetics Act, 1940 including on the Medical Devices Rules.
  • Assisted a leading biotechnology company focusing on the research and development of industrial enzymes and biopharmaceutical ingredients in setting up their manufacturing unit in India.
  • Advising and assisting Teleperformance SE, on the India leg of the transaction, with the acquisition of Intelenet group of companies from Blackstone; with a deal value of approximately USD 1 billion.
  • Advised and assisted a leading global provider of trading, clearing, exchange technology, listing, information and public company services, on the India leg of the transaction, with the sale of its public relations solutions and digital media services business; with a deal value of approximately USD 335 million.